Oruka Therapeutics (NASDAQ:ORKA) Shares Climb 8.4% – Should You Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares traded up 8.4% during mid-day trading on Tuesday. The company traded as high as $112.16 and last traded at $113.3830. Approximately 1,215,407 shares traded hands during trading, an increase of 13% from the average daily volume of 1,077,189 shares. The stock had previously closed at $104.56.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Guggenheim restated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 26th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Finally, Mizuho set a $120.00 price target on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $133.00.

Oruka Therapeutics Trading Up 6.9%

The firm has a market cap of $7.40 billion, a P/E ratio of -55.51 and a beta of -0.34. The firm has a 50-day simple moving average of $88.48 and a 200-day simple moving average of $70.92.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). Research analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the sale, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares in the company, valued at approximately $1,633,177.92. The trade was a 39.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 179,950 shares of company stock worth $16,492,680. 23.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nykredit A S purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $29,000. GAMMA Investing LLC boosted its holdings in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares in the last quarter. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the second quarter worth about $91,000. Sterling Capital Management LLC grew its stake in shares of Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after acquiring an additional 1,485 shares during the last quarter. Finally, Natural Investments LLC purchased a new stake in shares of Oruka Therapeutics during the second quarter worth about $202,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.